MP-AzeFlu improves allergic rhinitis severity regardless of disease phenotype: a real-life study

Ludger Klimek, David Price, Gabriella Galffy, Melanie Emmeluth, Arkady Koltun, Ferdinand Kopietz, Duc Tung Nguyen, Ranny Van Weissenbruch, Wolfgang Pohl, Hans Christian Kuhl, Glenis Scadding, Joaquim Mullol

Research output: Contribution to conferenceAbstract

Abstract

Background Phenotyping allergic rhinitis (AR) by IgE sensitivity and presence of comorbidities may help characterize allergic diseases, provide a clinical framework to inform treatment decisions, and improve clinical trial design. MP-AzeFlu (137µg azelastine hydrochloride + 50 µg fluticasone propionate intranasal spray) is a treatment for AR but the effectiveness of MP-AzeFlu on disease severity by AR phenotypes is unknown. This prospective, noninterventional study evaluated the effectiveness of MP AzeFlu (1 spray in each nostril twice daily for 2 weeks) across novel AR phenotypes.
Original languageEnglish
Publication statusPublished - 6 Jun 2020
EventEAACI Digital Congress 2020 - Digital, London, United Kingdom
Duration: 6 Jun 20208 Jun 2020

Conference

ConferenceEAACI Digital Congress 2020
CountryUnited Kingdom
CityLondon
Period6/06/208/06/20

Fingerprint Dive into the research topics of 'MP-AzeFlu improves allergic rhinitis severity regardless of disease phenotype: a real-life study'. Together they form a unique fingerprint.

Cite this